Figure 3 | Scientific Reports

Figure 3

From: Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study

Figure 3

Kaplan–Meier estimates of (A) progression-free and (B) overall survival according to LM and (C) progression-free and (D) overall survival according to IFI. FTD/TPI, trifluridine/tipiracil hydrochloride; RAM, ramucirumab; PFS, progression-free survival; OS, overall survival; LM, liver metastasis; IFI, anti-PD-1 inhibitor-free interval; mo., months; HR, hazard ratio; CI, confidence interval.

Back to article page